Jeff Jones
Stock Analyst at Oppenheimer
(1.92)
# 3,183
Out of 5,090 analysts
95
Total ratings
31.4%
Success rate
-4.23%
Average return
Main Sectors:
Stocks Rated by Jeff Jones
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PTHS Pelthos Therapeutics | Reiterates: Outperform | $50 → $57 | $26.57 | +114.53% | 2 | Nov 14, 2025 | |
| VTYX Ventyx Biosciences | Maintains: Outperform | $9 → $14 | $8.72 | +60.55% | 11 | Oct 27, 2025 | |
| KYMR Kymera Therapeutics | Maintains: Outperform | $53 → $63 | $66.62 | -5.43% | 6 | Oct 1, 2025 | |
| CMMB Chemomab Therapeutics | Maintains: Outperform | $10 → $25 | $2.48 | +908.06% | 9 | Aug 27, 2025 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Outperform | $56 → $53 | $10.24 | +417.58% | 10 | Aug 6, 2025 | |
| AVBP ArriVent BioPharma | Maintains: Outperform | $39 → $44 | $24.69 | +78.21% | 3 | Jun 24, 2025 | |
| ALMS Alumis | Maintains: Outperform | $26 → $25 | $11.12 | +124.82% | 3 | May 15, 2025 | |
| ZURA Zura Bio | Maintains: Outperform | $19 → $17 | $3.74 | +354.55% | 4 | May 9, 2025 | |
| CRVS Corvus Pharmaceuticals | Reiterates: Outperform | $15 → $17 | $8.81 | +92.96% | 5 | May 9, 2025 | |
| IMCR Immunocore Holdings | Maintains: Outperform | $85 → $86 | $38.78 | +121.76% | 2 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $28 → $18 | $3.94 | +356.85% | 4 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $3.77 | - | 5 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $22 → $16 | $2.40 | +566.67% | 7 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $45 | $1.21 | +3,619.01% | 6 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $16.66 | - | 4 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $1.10 | - | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $5.46 | - | 2 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $15 | $1.19 | +1,160.50% | 5 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $1,875 | $7.24 | +25,797.79% | 2 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $1,600 → $1,100 | $5.25 | +20,852.38% | 2 | Nov 17, 2022 |
Pelthos Therapeutics
Nov 14, 2025
Reiterates: Outperform
Price Target: $50 → $57
Current: $26.57
Upside: +114.53%
Ventyx Biosciences
Oct 27, 2025
Maintains: Outperform
Price Target: $9 → $14
Current: $8.72
Upside: +60.55%
Kymera Therapeutics
Oct 1, 2025
Maintains: Outperform
Price Target: $53 → $63
Current: $66.62
Upside: -5.43%
Chemomab Therapeutics
Aug 27, 2025
Maintains: Outperform
Price Target: $10 → $25
Current: $2.48
Upside: +908.06%
Corbus Pharmaceuticals Holdings
Aug 6, 2025
Maintains: Outperform
Price Target: $56 → $53
Current: $10.24
Upside: +417.58%
ArriVent BioPharma
Jun 24, 2025
Maintains: Outperform
Price Target: $39 → $44
Current: $24.69
Upside: +78.21%
Alumis
May 15, 2025
Maintains: Outperform
Price Target: $26 → $25
Current: $11.12
Upside: +124.82%
Zura Bio
May 9, 2025
Maintains: Outperform
Price Target: $19 → $17
Current: $3.74
Upside: +354.55%
Corvus Pharmaceuticals
May 9, 2025
Reiterates: Outperform
Price Target: $15 → $17
Current: $8.81
Upside: +92.96%
Immunocore Holdings
May 8, 2025
Maintains: Outperform
Price Target: $85 → $86
Current: $38.78
Upside: +121.76%
Jan 24, 2025
Maintains: Outperform
Price Target: $28 → $18
Current: $3.94
Upside: +356.85%
Dec 11, 2024
Downgrades: Perform
Price Target: n/a
Current: $3.77
Upside: -
Nov 22, 2024
Maintains: Outperform
Price Target: $22 → $16
Current: $2.40
Upside: +566.67%
Aug 8, 2024
Maintains: Outperform
Price Target: $48 → $45
Current: $1.21
Upside: +3,619.01%
Jun 7, 2024
Downgrades: Perform
Price Target: n/a
Current: $16.66
Upside: -
Apr 1, 2024
Reiterates: Perform
Price Target: n/a
Current: $1.10
Upside: -
May 23, 2023
Downgrades: Perform
Price Target: n/a
Current: $5.46
Upside: -
May 11, 2023
Reiterates: Outperform
Price Target: $15
Current: $1.19
Upside: +1,160.50%
Mar 24, 2023
Reiterates: Outperform
Price Target: $1,875
Current: $7.24
Upside: +25,797.79%
Nov 17, 2022
Maintains: Outperform
Price Target: $1,600 → $1,100
Current: $5.25
Upside: +20,852.38%